Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling

Executive Summary

Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval
Advertisement

Related Content

Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%
Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%
ADHD Class Warnings Could Be Strengthened Pending FDA Research
ADHD Class Warnings Could Be Strengthened Pending FDA Research
ADHD Drug Cardiovascular Risk Should Be Extended to Strattera, Cmte. Says
ADHD Drug Cardiovascular Risk Should Be Extended to Strattera, Cmte. Says
ADHD Drug Warnings In New Highlights Section Replaces Need For Black Box
ADHD Drug Safety Evaluation Could Start With Short Cardiac Function Studies
Daytrana Post-Marketing Study Of Skin Sensitization Urged By Committee
Shire Adderall XR Sales Suspended In Canada; FDA Stands By “Black Box”
Advertisement
UsernamePublicRestriction

Register

PS047075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel